Adjusted earnings per share for the quarter to June 29 fell to $2.77 from $2.82 in the same period a year ago, and topped the average analyst EPS estimate compiled by FactSet of $2.68.

Johnson & Johnson (NYSE:JNJ) on Wednesday reported a second-quarter 2025 adjusted earnings of $2.77 per share, down 1.8% year over year, beating the consensus of $2.68. The pharmaceutical giant reported sales of $23.

The move will occur in phases by the end of 2026, the company announced July 15. No jobs are being eliminated.

C.J. Gardner-Johnson said he "retracts" the comments he made about the Philadelphia Eagles after he was traded to the Houston Texans this offseason, when he said the team "probably won't see a ring without me.

The S&P 500 ticked 0.3% higher on Wednesday, July 16, 2025, as President Trump sought to ease concerns that a dismissal of Fed Chair Jerome Powell could be imminent.

A former PGA Tour player had his own calamity on the par-3 16th at Royal Portrush, calling it the most embarrassing shot of his career.

In the second quarter, J&J’s worldwide oncology sales shot up more than 20 per cent, offsetting declines in sales of its popular immune system medicine Stelara, which is facing a patent cliff. Sales in its smaller, medtech division increased 6 per cent.

Johnson shared yet another personal insight that nobody asked for: His jizz has substantially more microplastics in it than his blood does. On X on Tuesday, Johnson posted: “I have microplastics in my ejaculate.